Stage 4 breast cancer means the cancer has spread beyond the breast and nearby lymph nodes to distant parts of the body. It is also called metastatic breast cancer. The most common sites where breast cancer spreads are the bones, liver, lungs, and less commonly the brain or skin. The five-year relative survival rate for distant-stage breast cancer is 32.6%, though individual outcomes vary widely depending on where the cancer has spread and its biological subtype.
How Stage 4 Differs From Earlier Stages
Breast cancer staging runs from 0 through 4. Stages 0 through 3 describe cancer that is still confined to the breast, the surrounding tissue, or nearby lymph nodes. Stage 4 is defined by one specific factor: the cancer has metastasized to organs or tissues far from the original tumor. In the formal staging system, this is classified as M1, meaning distant metastasis is present. The size of the original breast tumor and the number of affected lymph nodes, which matter so much in earlier stages, become less important once the cancer has traveled to distant organs.
Not everyone with stage 4 breast cancer followed the same path to get there. About 90% to 95% of people with metastatic breast cancer were originally diagnosed at an earlier stage, received treatment, and later experienced a recurrence that spread to distant sites. This is called recurrent metastatic breast cancer. The remaining 5% to 10% are diagnosed with metastatic disease from the start, meaning the cancer had already spread by the time it was first detected. This is called de novo metastatic breast cancer.
Where Stage 4 Breast Cancer Spreads
Breast cancer cells that break away from the original tumor travel through the bloodstream or lymphatic system and can take root in other organs. Bone tissue is the most common destination, followed by the liver and lungs. Metastases can also develop in the brain or skin, though these sites are less frequent.
The location of metastases shapes the symptoms a person experiences. Bone metastases often cause deep, persistent pain in the back, hips, or ribs, and can weaken bones enough to cause fractures. Liver metastases may lead to abdominal pain, nausea, jaundice (yellowing of the skin or eyes), or unexplained weight loss. Lung metastases can cause shortness of breath, a chronic cough, or chest pain. Brain metastases may produce headaches, vision changes, dizziness, or difficulty with balance and coordination. Some people have metastases in more than one organ at the same time.
Why the Cancer’s Subtype Matters
When breast cancer is diagnosed, the tumor is tested for specific biological markers that influence both treatment options and prognosis. The three most important markers are estrogen receptor (ER), progesterone receptor (PR), and HER2 status. These markers divide breast cancer into subtypes, and each subtype behaves differently.
Hormone receptor-positive cancers (ER+ and/or PR+) tend to grow more slowly and generally have better survival outcomes than hormone receptor-negative cancers across all stages. HER2-positive cancers are driven by an overactive growth protein, making them aggressive but also responsive to therapies that specifically target that protein. Triple-negative breast cancer, which lacks all three markers, tends to have the worst survival rates because fewer targeted treatment options are available. In stage 3 disease, for example, the five-year survival for triple-negative breast cancer drops to roughly 49%, while hormone receptor-positive subtypes remain significantly higher.
These subtypes don’t just predict how the cancer will behave. They determine which treatments are most likely to work, making the biopsy results as important as the stage number itself.
Treatment Options for Stage 4
Treatment for stage 4 breast cancer focuses on controlling the disease, slowing its growth, and managing symptoms. Unlike earlier stages where the goal is often to eliminate the cancer entirely, metastatic treatment is typically ongoing, sometimes for years.
The specific approach depends heavily on the cancer’s subtype. For hormone receptor-positive metastatic breast cancer, hormone-blocking therapy is the first choice. These treatments starve the cancer of the hormones it needs to grow and can keep the disease stable for extended periods. For HER2-positive disease, targeted therapies that block the HER2 protein are central to treatment. Newer antibody-drug conjugates combine a targeted molecule with chemotherapy, delivering the drug directly to cancer cells while limiting damage to healthy tissue. In late 2025, the FDA approved one such combination for first-line treatment of HER2-positive metastatic breast cancer. For triple-negative breast cancer, chemotherapy remains the primary treatment, sometimes combined with immunotherapy.
Radiation or surgery may also be used in specific situations, such as treating a painful bone metastasis or removing a single brain metastasis, but these are targeted interventions rather than attempts to cure the disease.
What Monitoring Looks Like
Living with stage 4 breast cancer means regular imaging scans to track how the disease is responding to treatment. The frequency of these scans depends on the cancer’s subtype, the specific treatment being used, and how long someone has been on that treatment.
For hormone receptor-positive cancers on first-line therapy, scans are typically scheduled every 8 to 12 weeks. HER2-positive cancers on first-line treatment are often monitored every 9 weeks, with more frequent scans (every 6 to 9 weeks) for those on later treatment lines. Triple-negative breast cancer, which can change more rapidly, is usually scanned every 6 to 8 weeks. These intervals aren’t rigid. Oncologists adjust the schedule based on how well the treatment is working and whether new symptoms appear.
Understanding the Survival Statistics
The 32.6% five-year relative survival rate for distant-stage breast cancer, based on data from 2015 to 2021, represents an average across all subtypes and all patients. That number is improving as new targeted therapies become available, and it doesn’t capture the full picture for any individual person. Someone with hormone receptor-positive, HER2-positive disease who responds well to targeted therapy may live far longer than five years. Someone with triple-negative disease may face a more difficult trajectory.
It’s also worth noting that survival statistics are always looking backward. They reflect outcomes for people diagnosed years ago, many of whom did not have access to treatments available today. The gap between past statistics and current treatment options is real, and it is growing as new therapies continue to gain approval.
Palliative Care Is Not the Same as Hospice
Palliative care is sometimes misunderstood as end-of-life care, but it serves a completely different purpose for people with stage 4 breast cancer. Palliative care focuses on managing pain, nausea, fatigue, and emotional distress while active treatment continues. It works alongside cancer treatment, not instead of it. Hospice care, by contrast, begins when treatment is no longer being pursued and the focus shifts entirely to comfort.
Many oncology centers now integrate palliative care from the time of a metastatic diagnosis. This approach has been shown to improve quality of life and can even help people tolerate their cancer treatments better by keeping side effects under control.